Mustang Bio Inc (OQ:MBIO)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 377 PLANTATION STREET
WORCESTER MA 01605
Tel: N/A
Website: https://www.mustangbio.com
IR: See website
<
Key People
Michael S. Weiss
Executive Chairman of the Board
Manuel Litchman
President, Chief Executive Officer, Director
James B. Murphy
Interim Chief Financial Officer
Peter Carney
Interim Chief Accounting Officer
   
Business Overview
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs in cell and gene therapies into potential cures for cancers and rare genetic diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR-T) therapies across multiple cancers, as well as lentiviral gene therapies for severe combined immunodeficiency. Its pipeline is focused in three core areas: CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors and gene therapies for rare genetic disorders. It is developing a CAR T therapy for hematologic malignancies in partnership with Fred Hutch targeting CD20 (MB-106). In partnership with St. Jude, its X-linked Severe Combined Immunodeficiency (XSCID) gene therapy programs (MB-117 and MB-217) are being developed under an exclusive license to develop a potentially curative treatment for XSCID, a rare genetic immune system condition.
Financial Overview
For the fiscal year ended 31 December 2023, Mustang Bio Inc revenues was not reported. Net loss decreased 33% to $51.6M. Lower net loss reflects Research and development - Balancing val decrease of 34% to $38.5M (expense), General and administrative - Balancing decrease of 20% to $9.3M (expense), Stock-based Compensation in R&D decrease of 92% to $132K (expense).
Employees: 80 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $3.53M as of Dec 31, 2023
Annual revenue (TTM): $0.00M as of Dec 31, 2023
EBITDA (TTM): -$48.85M as of Dec 31, 2023
Net annual income (TTM): -$51.60M as of Dec 31, 2023
Free cash flow (TTM): -$49.54M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 10,390,132 as of Mar 8, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.